0001437749-22-010726.txt : 20220503 0001437749-22-010726.hdr.sgml : 20220503 20220503191216 ACCESSION NUMBER: 0001437749-22-010726 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220410 FILED AS OF DATE: 20220503 DATE AS OF CHANGE: 20220503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scott John K Jr. CENTRAL INDEX KEY: 0001753763 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35076 FILM NUMBER: 22889087 MAIL ADDRESS: STREET 1: 30 BLUE HERON DR. CITY: GREENWOOD VILLAGE STATE: CO ZIP: 80121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NAVIDEA BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000810509 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 311080091 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4995 BRADENTON AVENUE STREET 2: SUITE 240 CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147937500 MAIL ADDRESS: STREET 1: 4995 BRADENTON AVENUE STREET 2: SUITE 240 CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: NEOPROBE CORP DATE OF NAME CHANGE: 19940714 4 1 rdgdoc.xml FORM 4 X0306 4 2022-04-10 0000810509 NAVIDEA BIOPHARMACEUTICALS, INC. NAVB 0001753763 Scott John K Jr. 4995 BRADENTON AVE., SUITE 240 DUBLIN OH 43017 1 1 Common Stock 2022-04-30 4 A 0 2500 0 A 8093395 D Common Stock 10139 I By spouse and children Series G Redeemable Preferred Stock 2022-04-10 4 P 0 3260 A 3260 D Series E Redeemable Convertible Preferred Stock 2.30 2022-04-10 4 S 0 50000 2.30 D 2021-03-02 2022-09-02 Common Stock 2173913 0 D Series F Redeemable Convertible Preferred Stock 0.80 2022-04-10 4 P 0 1740 0.80 A 2022-04-10 Common Stock 2175000 1740 D Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of monthly non-employee director fees. Issuance deferred at the request of the Reporting Person. Includes 2,639 shares of Common Stock owned by the Reporting Person's spouse and 7,500 shares of Common Stock owned by the Reporting Person's children. The Reporting Person may be deemed to have shared voting and/or dispositive power with respect to such shares. Series E Redeemable Convertible Preferred Stock, par value $.001 per share, was exchanged for Series F Redeemable Convertible Preferred Stock, par value $.001 per share, and Series G Redeemable Preferred Stock, par value $.001 per share. Series F Redeemable Convertible Preferred Stock, par value $.001 per share, is convertible at any time and has no expiration date. /s/ Erika L. Eves for John K. Scott, Jr. by power of attorney 2022-05-03